Dr Reddys Laboratories (RDY) EBIAT (2016 - 2025)
Historic EBIAT for Dr Reddys Laboratories (RDY) over the last 17 years, with Q4 2025 value amounting to $133.6 million.
- Dr Reddys Laboratories' EBIAT fell 1965.63% to $133.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $645.1 million, marking a year-over-year increase of 20745.21%. This contributed to the annual value of $671.0 million for FY2025, which is 44.91% up from last year.
- Per Dr Reddys Laboratories' latest filing, its EBIAT stood at $133.6 million for Q4 2025, which was down 1965.63% from $163.5 million recorded in Q3 2025.
- Dr Reddys Laboratories' 5-year EBIAT high stood at $996.4 million for Q3 2024, and its period low was -$1.9 billion during Q1 2024.
- Moreover, its 5-year median value for EBIAT was $158.8 million (2022), whereas its average is $109.9 million.
- Its EBIAT has fluctuated over the past 5 years, first skyrocketed by 11778634501.85% in 2023, then plummeted by 124197.34% in 2024.
- Quarter analysis of 5 years shows Dr Reddys Laboratories' EBIAT stood at $11.0 million in 2021, then soared by 962.09% to $116.8 million in 2022, then soared by 666.15% to $895.1 million in 2023, then crashed by 81.43% to $166.3 million in 2024, then decreased by 19.66% to $133.6 million in 2025.
- Its EBIAT was $133.6 million in Q4 2025, compared to $163.5 million in Q3 2025 and $164.7 million in Q2 2025.